RNS Number : 1886E
AstraZeneca PLC
13 September 2024
 

13 September 2024 15:15 BST

 

 

Transaction by Person Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announces that Michel Demaré, Non-Executive Chair of the Board, purchased 2,000 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 13 September 2024.

 

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Michel Demaré

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Chair of the Board

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

AstraZeneca PLC

b)

 

LEI

 

 

PY6ZZQWO2IZFZC3IOL08

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

 

 

b)

 

Nature of the transaction

 

 

Purchase of AstraZeneca PLC Ordinary Shares of US$0.25

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£117.927465

2,000

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

 

13 September 2024

f)

 

Place of the transaction

 

 

LON

 

 

AstraZeneca 

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca 

 

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Adrian Kemp
Company Secretary

AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUOAORSAUKAAR